Overview: Upadacitinib Shows Promising 1-Year Benefit in Pediatric IBD New findings from a real-world, single-center study suggest that upadacitinib (Rinvoq) can offer durable clinical benefits for children and adolescents with inflammatory bowel disease (IBD) over a 12-month period. The retrospective study followed 48 pediatric patients diagnosed with Crohn’s disease (CD) or ulcerative colitis (UC), exploring…